Table 1.
Patient characteristics of five subjects undergoing bariatric surgery during treatment with gabapentin (patients 1-2) or pregabalin (patients 3-5).
Table 2.
Pharmacokinetic parameters preoperatively (baseline) and 1, 6 and 12 months postoperatively. In patients not using the same dose throughout the study, concentrations were adjusted to the main dose for that subject. All changes are displayed relative to preoperatively.
Fig 1.
Individual time-concentration plots at baseline (preoperatively) and 1, 6 and 12 months postoperatively.
In patients not using the same daily dose during the study, concentrations were adjusted to the main dose for that subject (Table 1). Note that the scale on the y-axis varies between subjects. RYGB = Roux-en-Y gastric bypass; SG = sleeve gastrectomy; b.d. = twice a day; t.d.s. = three times a day.
Fig 2.
Pharmacokinetic parameters at baseline (preoperatively) and 1, 6 and 12 months after bariatric surgery in two patients treated with gabapentin (patients 1-2) and three patients treated with pregabalin (patients 3-5).
Patient 1 underwent sleeve gastrectomy whereas the others underwent Roux-en-Y gastric bypass.
Fig 3.
Body mass index (BMI), body fat, total body water and muscle mass at baseline (preoperatively) and 1, 6 and 12 months after bariatric surgery in two patients treated with gabapentin (patients 1-2) and three patients treated with pregabalin (patients 3-5).
Patient 1 underwent sleeve gastrectomy whereas the others underwent Roux-en-Y gastric bypass.